INNOVUS PHARMACEUTICALS, INC. (OTCMKTS:INNV) Files An 8-K Entry into a Material Definitive AgreementItem 1.01 Entry into a Material Definitive Agreement.
INNOVUS PHARMACEUTICALS, INC. (OTCMKTS:INNV) Files An 8-K Entry into a Material Definitive Agreement
On November 29, 2016, the Company announced that it had entered into an exclusive license and distribution agreement with J&H Co. LTD for the commercialization of Zestra® in South Korea. The exclusive 10-year agreement includes a minimum of $2 million per year in sales to the Company for a total of $20 million over the life of the agreement.
A copy of the press release regarding the above-described agreement is attached as Exhibit 99.1 and incorporated by reference into this Current Report on Form 8-K.
Item 9.01 Financial Statements and Exhibits.
(d)
Exhibits.
99.1
Press Release issued November 29, 2016
About INNOVUS PHARMACEUTICALS, INC. (OTCMKTS:INNV)
Innovus Pharmaceuticals, Inc. is a pharmaceutical company engaged in the commercialization, licensing, and development of non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases. The Company markets approximately five products in the United States and six in a range of countries around the world through its commercial partners. It has commercial agreements in over 60 countries around the world through its commercial partners. Its marketed products include Zestra, EjectDelay, Sensum+, Zestra Glide, Vesele and Androferti. In addition, the Company has a pipeline of over three additional products, including FlutiCare Over-The-Counter (OTC) for Allergic Rhinitis; Urocis XR, an extended release of Vaccinium Marcocarpon (cranberry), and AndroVit, a supplement to support overall prostate and male sexual health, which is marketed in Europe. INNOVUS PHARMACEUTICALS, INC. (OTCMKTS:INNV) Recent Trading Information
INNOVUS PHARMACEUTICALS, INC. (OTCMKTS:INNV) closed its last trading session down -0.002 at 0.250 with 316,610 shares trading hands.
Innovus Pharmaceuticals, Inc. is a pharmaceutical company engaged in the commercialization, licensing, and development of non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases. The Company markets approximately five products in the United States and six in a range of countries around the world through its commercial partners. It has commercial agreements in over 60 countries around the world through its commercial partners. Its marketed products include Zestra, EjectDelay, Sensum+, Zestra Glide, Vesele and Androferti. In addition, the Company has a pipeline of over three additional products, including FlutiCare Over-The-Counter (OTC) for Allergic Rhinitis; Urocis XR, an extended release of Vaccinium Marcocarpon (cranberry), and AndroVit, a supplement to support overall prostate and male sexual health, which is marketed in Europe. INNOVUS PHARMACEUTICALS, INC. (OTCMKTS:INNV) Recent Trading Information
INNOVUS PHARMACEUTICALS, INC. (OTCMKTS:INNV) closed its last trading session down -0.002 at 0.250 with 316,610 shares trading hands.
